Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

Centrexion Therapeutics

Status and phase: Not yet enrolling; Phase 1

Conditions: Lower Back Pain

Treatments: Drug: Placebo; Drug: CNTX-3001

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT07122453

CNTX-3001it-LBP-101

1UG3NS123965-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past.

CNTX-3001 is a novel, non-opioid small molecule

Enrollment: 16 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Have stable intractable, chronic moderate to severe low back pain

• Must have failed all 3 of the following categories of therapies:

  1. Physical medicine modalities for at least 6 weeks (e.g., physical therapy, occupational therapy, or chiropractic treatment directed at chronic low back pain)
  2. Three or more classes of pharmacologic treatments
  3. One or more non-surgical and/or surgical interventions addressing the primary cause of chronic low back pain

• If the intractable low back pain is accompanied by radicular pain, back pain must be dominant over leg pain and may not radiate below the knee

• Has normal leg strength in both legs (able to stand/walk)

• Willing and able to undergo the lumbar puncture

• On a stable analgesic regimen, or a stable dose of an opioid medication for >3 months

• Non- or ex-smoker and has not used any nicotine-containing products within 3 months

• Men or women able to abide by reproductive and contraceptive requirements

• Has a body mass index (BMI) between 18 and 35 kg/m2, with weight ≥60 kg

Exclusion

• Substantial increase or decrease in pain over the prior 3 months.
• Low back pain that only occurs with specific activities or body positions.
• Has asthma or other severe respiratory disease requiring daily prescription medication
• History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders
• Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis

Exclusion

• Substantial increase or decrease in pain over the prior 3 months
• Low back pain that only occurs with specific activities or body positions
• Has asthma or other severe respiratory disease requiring daily prescription medication
• History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders
• Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

16 participants in 2 patient groups, including a placebo group

CNTX-3001

Experimental group

Description:

Single intrathecal injection of CNTX-3001

Treatment:

Drug: CNTX-3001

Placebo

Placebo Comparator group

Description:

Single intrathecal injection of normal saline

Treatment:

Drug: Placebo